The US drugs regulator has approved the sale of a new nasal spray to treat depression. Manufacturer Janssen says Esketamine can ... and can cost up to $885 (£673) per treatment.

An esketamine-based nasal spray antidepressant for adults is under review in the US following a filing from Johnson & Johnson's pharma unit. Janssen has submitted a filing for esketamine to the US ...

Janssen, which is Johnson & Johnson’s pharma unit, submitted a filing to the European Medicines Agency for esketamine nasal spray, which is designed to help people with treatment-resistant ...

Results, published in CNS Spectrums, showed a significant improvement in symptoms for those taking a new OAD with esketamine ...